These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3044323)

  • 21. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G; Goossens H; Seemann K; Souchon F; Weitz T
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1881-5. PubMed ID: 6499689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
    Galle RR; Gusakova GA; Sabaev VV; Galle NN
    Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
    [No Abstract]   [Full Text] [Related]  

  • 23. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scopoderm: transdermal hyoscine for motion sickness.
    Drug Ther Bull; 1989 Nov; 27(23):91-2. PubMed ID: 2519317
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of cinnarizine in the prevention of seasickness.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of drooling using transdermal scopolamine skin patches. A case report.
    Mato Montero A; Limeres Posse J; Tomás Carmona I; Fernández Feijoo J; Diz Dios P
    Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E27-30. PubMed ID: 18167476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea.
    Gordon CR; Doweck I; Nachum Z; Gonen A; Spitzer O; Shupak A
    J Vestib Res; 2003; 13(2-3):103-11. PubMed ID: 14757913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The vestibulo-ocular reflex (VOR) under the influence of cinnarizine.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    J Vestib Res; 1994; 4(3):215-20. PubMed ID: 7921339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

  • 36. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.
    Sah N; Ramesh V; Kaul B; Dalby P; Shestak K; Vallejo MC
    J Clin Anesth; 2009 Jun; 21(4):249-52. PubMed ID: 19502023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prophylaxis of seasickness. A comparison of cinnarizine with hyoscine.
    Hargreaves J
    Practitioner; 1982 Jan; 226(1363):160. PubMed ID: 7043439
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K; Zahner G; Dietlein G; Franz I
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.